D J Kuter

..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP...

..This suggests new avenues for investigation into the pathogenesis of various disorders associated with increased bone marrow stromal fibres...

..Future studies will assess the utility of romiplostim in CIT, hepatitis-C related thrombocytopenia, and MDS...

..Overall, treatment of ITP was associated with improvement in HRQOL. Patients receiving romiplostim had greater HRQOL improvements than those receiving SOC, but the magnitude ofthe difference is of uncertain clinical benefit...

..Their impact on platelet usage is still unclear but may be less than initially estimated...

..One or more second-generation thrombopoietic growth factors should soon be clinically available for treating thrombocytopenic disorders...

..Ongoing studies should establish the incidence of these complications and determine the efficacy of these new agents in a variety of other thrombocytopenic conditions...

..These studies were registered at www.clinicaltrials.gov as #NCT00102323, #NCT00102336, #NCT00861224, and #NCT00116688...

..Studies are under way to assess the efficacy of these drugs in the treatment of other thrombocytopenic disorders associated with chemotherapy, myelodysplasia, and chronic hepatitis...

..Both have been highly effective in increasing the platelet count in patients with ITP and are currently being studied in the treatment of other thrombocytopenic conditions (myelodysplastic syndrome, chemotherapy, liver disease)...

..Newer anticoagulant treatments, such as pentasaccharide and direct thrombin inhibitors, need to be explored to address this major medical problem...

..Ongoing and future studies will help define the clinical role of recombinant TPO and TPO mimetics in the treatment of chemotherapy- and nonchemotherapy-induced thrombocytopenia...

..Thrombopoietin therapy can increase platelet counts in healthy donors to provide a median 3-fold more apheresis platelets compared with untreated donors...

....

..These data demonstrate a new mechanism for thrombocytopenia in which antibody develops to TPO; because endogenous TPO is produced constitutively, thrombocytopenia ensues...

..Given the increasing number of studies establishing the clinical efficacy of low molecular weight heparins as antithrombotic agents, these results suggest that TFPI may not be a major contributor to the antithrombotic effect of heparin...

..This review summarizes recent research progress on megakaryocyte apoptosis and platelet release...

..Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects...

..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...

..These results serve as a proof that the circulating level of TPO is determined not by alterations in TPO transcription or translation but by the ability of the platelet mass to bind and remove TPO from the circulation...

..Although ineffective here, inhibition of PLT apoptosis may improve PLT cellular viability...

..Efforts to use prophylactic heparin or warfarin to reduce catheter-related DVT have not been rewarding...

..Whether anticoagulants might also improve cancer survival rates independent of their effect on thromboembolism deserves further investigation...

..This article reviews the biology of TPO, the regulation of its circulating level in ITP, the platelet kinetic data supporting inappropriate platelet production in ITP, and the TPO mimetic agents available to treat ITP...

....

..CD36, a transmembrane protein present on endothelial cells and platelets (PLTs), binds to thrombospondin via three thrombospondin type 1 repeats. ADAMTS13 contains eight thrombospondin type 1 repeats...

..However, the clearance of argatroban was prolonged. CONCLUSIONS: This case illustrates that supratherapeutic doses of argatroban can be managed with FFP and tolerated without significant complications...

..Clinically significant thrombocytopenia was uncommon in our analysis, and linezolid was not associated with a greater risk of thrombocytopenia in seriously ill patients than was vancomycin...

..The patient remains in complete remission and on no other therapy for 36 months following the autologous HSCT...

..2 +/- 1.5 x 10(9)/L; P < .001). CONCLUSION: Biochemically confirmed tobacco abstinence leads to a rapid and sustained decrease in WBC and ANC, possibly reflecting a decrease In an underlying state of tobacco-induced inflammation...

..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP...

..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...

..Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use...